Change of chief executive officer at Sanofi

Paul Hudson is to succeed Olivier Brandicourt as Chief Executive Officer at Sanofi. 

Paul Hudson is to succeed Olivier Brandicourt as Chief Executive Officer at Sanofi.

Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.

The Board of Directors expressed their thanks to Olivier Brandicourt for the energy with which he has steered the Group through a complex period and for his decisive contribution to the company’s return to growth. They said that thanks to the actions undertaken during his term of office, Sanofi is able to accelerate its growth, and has powerful assets to regain the position it needs to occupy.

On 1 September 2019, Brandicourt will be replaced by Paul Hudson, who most recently was
Chief Executive Officer of Novartis Pharmaceuticals and Member of the Executive Committee of Novartis.

Sanofi states that Paul Hudson is a seasoned leader with a strong international experience, particularly in the United States, Japan and Europe. He spent his 28-year career with major pharmaceutical companies such as Schering Plough, AstraZeneca and Novartis. Throughout his various management positions, he has proven his strategic vision, his strong leadership and his ability to achieve the greatest challenges, particularly in terms of innovation and digital transformation. Mr. Hudson has a very robust track record in successful major product launches.

Serge Weinberg, Chairman of the Board of Directors of Sanofi, said: “We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group’s adaptation to new strategic challenges, particularly in the areas of research and development and digital. His human values will enable him to mobilise all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world.”


Related news

Sanofi’s Dupixent®▼ (dupilumab) licensed in EU

Sanofi appoints Chief Digital Officer